Pluri (PLUR) Non-Current Assets (2011 - 2025)
Pluri (PLUR) posted quarterly Non-Current Assets of $16.8 million for Q4 2025, up 97.76% year-over-year from $8.5 million in Q4 2024, and little changed quarter-over-quarter from $16.8 million in Q3 2025.
Pluri (PLUR) Non-Current Assets (2011 - 2025) Analysis & Trends
Pluri (PLUR) has reported Non-Current Assets for 15 consecutive years, with $16.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Assets rose 97.76% year-over-year to $16.8 million; the TTM figure through Dec 2025 stood at $16.8 million (up 97.76% YoY), while the FY2025 annual figure was $16.6 million, up 97.01% from the prior year.
- Non-Current Assets held at $16.8 million in Q4 2025 per PLUR's latest filing, from $16.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $29.4 million in Q1 2021 and bottomed at $8.4 million in Q3 2024.
- Historically, Non-Current Assets has averaged $13.7 million across 5 years, with a median of $10.0 million in 2022.
- Annual changes were most pronounced in 2021 — Non-Current Assets surged 464.39% — and 2022, when it tumbled 60.57%.
- Pluri's Non-Current Assets stood at $21.0 million in 2021, then tumbled by 53.46% to $9.8 million in 2022, then dropped by 4.85% to $9.3 million in 2023, then decreased by 8.82% to $8.5 million in 2024, then jumped by 97.76% to $16.8 million in 2025.
- Business Quant data shows PLUR's Non-Current Assets at $16.8 million in Q4 2025, $16.8 million in Q3 2025, and $16.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 18.06 Bn |
| 10 | Pluri | 16.21 Mn | 3.72 Mn | 86,000.00 | 16.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.79 Mn |
| Sep 30, 2025 | 16.75 Mn |
| Jun 30, 2025 | 16.59 Mn |
| Mar 31, 2025 | 9.95 Mn |
| Dec 31, 2024 | 8.49 Mn |
| Sep 30, 2024 | 8.41 Mn |
| Jun 30, 2024 | 8.42 Mn |
| Mar 31, 2024 | 9.02 Mn |
| Dec 31, 2023 | 9.31 Mn |
| Sep 30, 2023 | 9.28 Mn |
| Jun 30, 2023 | 9.39 Mn |
| Mar 31, 2023 | 9.55 Mn |
| Dec 31, 2022 | 9.79 Mn |
| Sep 30, 2022 | 10.03 Mn |
| Jun 30, 2022 | 10.32 Mn |
| Mar 31, 2022 | 14.81 Mn |
| Dec 31, 2021 | 21.03 Mn |
| Sep 30, 2021 | 20.92 Mn |
| Jun 30, 2021 | 26.17 Mn |
| Mar 31, 2021 | 29.35 Mn |